HOME >> BIOLOGY >> NEWS
Targeting key proteins of carcinogenesis

among experts.

A prerequisite for the E3-independent reaction is the presence of a Ub-binding domain (UBD) in the protein that is able to recognize Ub. This type of protein is of utmost importance for the cell because it can distinguish between ubiquitinated and non-ubiquitinated proteins, explains Dr. Daniela Hoeller, the responsible scientist. UBD-proteins are the key to the effects of Ub both in normal and malignant cells.

Dikic and his coworkers demonstrated that proteins equipped with an UBD can ubiquitinate themselves by directly recruiting Ub-loaded E2 enzymes thus making E3 ligases dispensible. In their previous work Hoeller and Dikic showed that the ubiquitination of UBD proteins does not lead to their degradation but rather causes their functional inactivation. In other words they become unable to recognize and control ubiquitinated proteins. If needed the cell can re-activated them by cleaving the attached Ub. In this way the cell can quickly and dynamically react on external signals.

The discovery provides the basis for novel therapeutic approaches that are more specific than drugs like Bortezomib. For an effective therapeutic use there is still a long way to go, explains Mller-Esterl, who needs to update his biochemistry textbook now.


'"/>

Contact: Ivan Dikic
ivan.dikic@biochem2.de
49-696-301-4862
Johann Wolfgang Goethe-Universitt Frankfurt
22-Jun-2007


Page: 1 2

Related biology news :

1. Targeting tumors the natural way
2. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
6. Targeting lung cancer
7. Targeting the dosage compensation complex
8. Targeting pancreatic cancer
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Targeting tumor growth
11. UCF research links proteins, stem cells and potential Alzheimers treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... -- AIC announces that it has just released a new white paper authored by Zettar ... high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... UK (PRWEB) , ... December 08, 2016 , ... ... precision light to control cells — optogenetics — is key to exciting advances ... of the art, spatially patterned light projected via free-space optics stimulates small, transparent ...
(Date:12/8/2016)... England , December 8, 2016 ... has expanded its customisable SureSeq™ NGS panel range with the ... allowing fast and cost-effective study of variants in familial hypercholesterolemia ... number variation (CNV) detection on a single small panel and ... hotspot content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
Breaking Biology Technology:
Cached News: